ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Peng, Lun-Xi; Jie, Guang-Ling; Li, An-Na; Liu, Si-Yang; Sun, Hao; Zheng, Mei-Mei; Zhou, Jia-Ying; Zhang, Jia-Tao; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Yang, Jin-Ji; Tu, Hai-Yan; Su, Jian; Yan, Hong-Hong; Wu, Yi-Long*广东省人民医院; 南方医科大学
Experimental Hematology & Oncology2021-11-10DOI: 10.1186/s40164-021-00245-y
24被引4阅读
引用收藏
分享

摘要

Background MET amplification plays an important role in the development of non-small-cell lung cancer (NSCLC) either de novo or in resistance to epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI) settings. Fluorescence in situ hybridization (FISH) is the standard method for MET amplification. With more and more discoveries of oncogenic driver genes, next-generation sequencing (NGS) plays a significant role in precision oncology. Meanwhile, the role of NGS in MET amplification remains uncertain. Methods Forty patients diagnosed with advanced NSCLC were included. FISH and NGS were conducted prior to MET inhibitors treatment. MET amplification by FISH was defined as a MET/CEP7 ratio of > 2.0 and/or copy number (CN) > 5. MET amplification by NGS was defined as gene copy number (GCN) >= 5. Results The concordance rate among FISH and NGS was 62.5% (25/40). MET amplification identified by FISH showed the optimal predictive value. The partial response (PR) rate was 68.0% (17/25 with MET amplification) vs. 6.7% (1/15 without MET amplification); the median progression-free survival (PFS) was 5.4 months versus 1.0 months (P < 0.001). MET amplification identified by NGS failed to distinguish significant clinical outcomes. The PR rate was 60.0% (6/10, with MET GCN >= 5) vs. 40.0% (12/30, with MET GCN < 5); the median PFS was 4.8 months vs. 2.2 months (P = 0.357). The PR rate was 68.8% (11/16) and the median PFS was 4.8 months in patients with focal amplification by NGS. Conclusions MET amplification identified by FISH remains the optimal biomarker to identify suitable candidates for MET-TKI therapy. In comparison, amplification identified by NGS seems not as robust to be effective predictive biomarker. Further exploration is needed regarding the focal amplification by NGS in predicting the efficacy.

学科与关键词

关键词
FISH-NGSMET amplificationPredictive factorsSurvival benefits
相关
加载中…
  • NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker
    Peng, L.; Li, A.; Liu, S.; Sun, H.; Zheng, M.; Zhou, J.; Zhang, J.; Zhang, X.; Zhou, Q.; Zhong, W.; Yang, X.; Tu, H.; Su, J.; Yan, H.; Gou, L.; Gao, H.; Wu, Y.被引 1
  • Clinical outcomes of EGFR plus /METamp plus vs. EGFR plus /METamp- untreated patients with advanced non-small cell lung cancer
    Peng, Kai-Cheng; Su, Jun-Wei; Xie, Zhi; Wang, Han-Min; Fang, Mei-Mei; Li, Wen-Feng; Chen, Yu-Qing; Guan, Xu-Hui; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Tu, Hai-Yan; Zhou, Qing; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji*Thoracic Cancer, 2022, 13(11): 1619-1630.被引 5
  • Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer
    Su, Shan; Lin, Anqi; Luo, Peng; Zou, Jianjun; Huang, Zhihao; Wang, Xiaojun; Zeng, Yunyun; Cen, Wenchang; Zhang, Xianlan; Huang, Huiyi; Hu, Jinxing*; Zhang, Jian*Annals of Translational Medicine, 2021, 9(18): 1475.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Experimental Hematology & Oncology
发表日期
2021-11-10
卷期
第 10 卷, 第 1 期
页码
52
DOI
10.1186/s40164-021-00245-y
期刊等级
4区
成果收录
SCIE
资助标注
National Key R&D Program of China [2016YFC1303800]; Special Fund of Public Interest, the National Health and Family Control Committee [201402031]; Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • P

    Peng, Lun-Xi (第一作者)

    guangdong prov peoples hosp · 2 · southern med univ

  • J

    Jie, Guang-Ling

    guangdong prov peoples hosp

查看全部 16 位作者收起作者
  • L

    Li, An-Na

    guangdong prov peoples hosp

  • L

    Liu, Si-Yang

    guangdong prov peoples hosp

  • S

    Sun, Hao

    guangdong prov peoples hosp

  • Z

    Zheng, Mei-Mei

    guangdong prov peoples hosp

  • Z

    Zhou, Jia-Ying

    guangdong prov peoples hosp

  • Z

    Zhang, Jia-Tao

    guangdong prov peoples hosp · 2 · southern med univ

  • Z

    Zhang, Xu-Chao

    guangdong prov peoples hosp · 2 · southern med univ

  • Z

    Zhou, Qing

    guangdong prov peoples hosp · 2 · southern med univ

  • Z

    Zhong, Wen-Zhao

    guangdong prov peoples hosp · 2 · southern med univ

  • Y

    Yang, Jin-Ji

    guangdong prov peoples hosp · 2 · southern med univ

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp

  • S

    Su, Jian

    guangdong prov peoples hosp

  • Y

    Yan, Hong-Hong

    guangdong prov peoples hosp

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp · 2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417